Atlas Trials

Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell Lymphoma

Clinical trial NCT05348213 · RECRUITING

Trial details

NCT number
NCT05348213
Sponsor
Ruijin Hospital
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Diffuse Large B Cell Lymphoma
Start date
2022-05-16
Primary completion
2025-06-01
Enrollment
76

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.